#Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Share

[industryforecastnews]

Healthcare Contract Development And Manufacturing Organization Market To Reach USD 471.0 Billion By 2030

Healthcare Contract Development and Manufacturing Organization Market Growth & Trends

The global healthcare contract development and manufacturing organization market size is expected to reach USD 471.0 billion by 2030, growing at a CAGR of 9.68% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to show lucrative growth due to rising outsourcing trends and increasing R&D expenditure.

Healthcare contract development and manufacturing organization (CDMO) provide outsourcing services to various pharmaceutical industries on a contract basis. An increase in outsourcing by pharmaceutical companies, expansions in the pharmaceutical industry, and the support of CDMOs in reducing operational and capital expenses are some of the major factors anticipated to propel the market growth in the forecast period.

In addition, growing requirement among pharmaceutical and medical device companies to follow stringent timelines has increased the demand for outsourcing development and manufacturing activities to CDMOs. Further, due to the increasing demand for medical devices in emerging countries, various companies are shifting their focus on research and development activities for medical device contract development and manufacturing. Over the past 10 years, several pharmaceutical companies have turned to CMOs, CROs, and CDMOs to assist in pre-formulation and development & manufacturing of their novel innovations. Outsourcing is a high growth market, and most spending is focused on early development.

Around 75% of new drug pipelines come from small- and midsized biopharmaceutical companies. These companies have high profit margins, which make them easy targets for healthcare providers who are trying to reduce costs. Thus, instead of investing in establishing their own infrastructure, it is profitable for these companies to outsource services to third-party organizations that have expertise and the required equipment. Several pharmaceutical companies are seeking outsourced services for optimizing the development of their molecules. Furthermore, a large number of CDMO collaborations, expansions, mergers & acquisitions, and other strategic initiatives undertaken by market players operating in the country are anticipated to boost the market. For instance, In March 2023, Remedium Bio, a U.S.-based biotechnology company, entered into a collaboration agreement with Exothera, a Belgium-based CDMO, to scale up the production of Remedium’s lead gene therapy drug candidate, AAV2-FGF18 in the treatment of osteoarthritis. Similarly, in January 2024, Enzene Biosciences, a subsidiary of Alkem Labs announced the manufacturing site in the U.S. Such innovations are anticipated to drive the market.

However, increasing logistic costs, serialization issues faced by healthcare organizations, and the threat of infringement of Intellectual Property (IP) rights are anticipated to restrain the market growth for healthcare contract development & manufacturing organization over the forecast period.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/healthcare-contract-development-manufacturing-organization-market

Healthcare Contract Development and Manufacturing Organization Market Report Highlights

Based on services, the contract manufacturing segment dominated the market with a revenue share of 73.50% in 2023 due to increase in the outsourcing of manufacturing services by pharmaceutical and medical device companies.In addition, cost-effectiveness, and the increasing number of CMOs are some of the key factors that are positively affecting the market growth

By small molecule contract development sub-segment, the preclinical/segment is expected to register the highest CAGR of 9.53% in the forecast period due to the rising pipeline of novel therapeutics

North America dominated the healthcare contract development and manufacturing organization industry with the largest revenue share of 40.91%in 2023. High shares of the region are majorly due to the presence of a large number of actively functioning CROs and CMOs in the region, especially across the U.S.

Healthcare Contract Development and Manufacturing Organization Market Segmentation

For this study, Grand View Research has segmented the healthcare contract development and manufacturing organization market based on services and region:

Healthcare CDMO Services Outlook (Revenue, USD Billion, 2018 - 2030)

Contract Development

Small Molecule

Preclinical

Bioanalysis and DMPK Studies

Toxicology Testing

Other Preclinical Services

Clinical

Phase I

Phase II

Phase III

Phase IV

Laboratory Services

Bioanalytical Services

Analytical Services

Large Molecule

Cell Line development

Process Development

Upstream

Microbial

Mammalian

Others

Downstream

MABs

Recombinant Proteins

Others

Others

Contract Manufacturing

Small Molecule

Large Molecule

MABs

Recombinant Proteins

Others

High Potency API

Finished Dose Formulations

Solid Dose Formulation

Liquid Dose Formulation

Injectable Dose Formulation

Medical Devices

Class I

Class II

Class III

Healthcare CDMO Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

U.S.                

Canada

Europe

Germany

UK

France

Italy

Spain

Netherlands

Belgium

Denmark

Norway

Sweden

Asia Pacific

China

India

Japan

Australia

South Korea

Malaysia

New Zealand

Singapore

Philippines

Thailand

Latin America

Brazil

Mexico

Argentina

Colombia

Chile

Middle East & Africa

South Africa

Saudi Arabia

UAE

Israel

Kuwait

List of Key Players in the Healthcare CDMO Market

Catalent Inc.

Lonza

Recipharm AB

Siegfried Holding AG

Thermo Fisher Scientific, Inc.

Labcorp Drug Development

Jabil Inc

Syngene International Limited

IQVIA Inc.

Almac Group

Ajinomoto Bio-Pharma

Adare Pharma Solutions

Alcami Corporation

Vetter Pharma International

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/healthcare-contract-development-manufacturing-organization-market

[tamanna31]

Small Molecule Innovator CDMO Market - The Biggest Trends to watch out for 2024-2030

Small Molecule Innovator CDMO Industry Overview

The global small molecule innovator CDMO market size was estimated at USD 48.6 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 6.21% from 2024 to 2030. Key drivers for this growth are increasing pharmaceutical R&D investment, growing demand for small molecules, and rising incidence of cancer & age-related disorders. Biological drugs are more expensive than small molecules. Hence, growing demand for cost-effective drugs is expected to further support market growth.

The COVID-19 pandemic significantly impacted on global economy in 2020 and caused an ongoing impact on various industries. However, the market for contract development and manufacturing organization (CDMO) witnessed a positive impact due to this pandemic. CDMOs played an important role in meeting the needs of pharmaceutical companies, biotech companies, and other end-users during this crisis. Overall, pandemic boosted market demand for small molecule innovator drugs. With the growing demand for outsourcing by pharma companies, heightened demand is observed in post-pandemic scenario.

Gather more insights about the market drivers, restrains and growth of the Small Molecule Innovator CDMO Market

Small Molecule Innovator CDMO Market Segmentation

Grand View Research has segmented the global small molecule innovator CDMO market based on product, stage type, customer type, therapeutic area, and region:

Small Molecule Innovator CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)

Small Molecule API

Small Molecule Drug Product

Oral solid dose

Semi-Solid Dose

Liquid Dose

Others

Small Molecule Innovator CDMO Stage Type Outlook (Revenue, USD Million, 2018 - 2030)

Preclinical

Clinical

Phase I

Small

Medium

Large

Phase II

Small

Medium

Large

Phase III

Small

Medium

Large

Commercial

Small Molecule Innovator CDMO Customer Type Outlook (Revenue, USD Million, 2018 - 2030)

Pharmaceutical

Small

Medium

Large

Biotechnology

Small Molecule Innovator CDMO Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

Cardiovascular disease

Oncology

Respiratory disorders

Neurology

Metabolic disorders

Infectious disease

Others

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global intrauterine devices marketsize was estimated at USD 6.25 billion in 2023 and is projected to grow at a CAGR of 3.66% from 2024 to 2030.

The global dual chamber prefilled syringes marketsize was valued at USD 167.3 million in 2023 and is projected to grow at a CAGR of 5.8% from 2024 to 2030.

Key Companies & Market Share Insights

Companies are undertaking various strategic initiatives to gain a competitive advantage. Key parameters affecting the competitive nature of the market include acquisition, geographic expansion, mergers, acquisitions, and product launches.

In September 2022, WuXi STA inaugurated a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. The integrated drug product platform CRDMO provides a full range of services, including solid-state development, pre-formulation, and clinical to commercial drug product manufacturing.

In June 2022, Lonza inaugurated a new clinical phase development and manufacturing facility in its small molecules site in Bend, Oregon. It is dedicated to manufacturing bioavailability-enhancing spray-dried dispersion (SDD) finished dosage forms and drug product intermediates

List of Key Players of Small Molecule Innovator CDMO Market

Piramal Pharma Solutions

CordenPharma International

Wuxi AppTec

Cambrex Corporation

Recipharm AB

Pantheon (Thermo Fisher Scientific)

Lonza

Catalent Inc.

Siegfried Holding AG

Boehringer Ingelheim

Labcorp Drug Development

Order a free sample PDF of the Small Molecule Innovator CDMO Market Intelligence Study, published by Grand View Research.

[health-views-updates]

CMO/CDMO Market Insights: Trends and Forecast for 2024

CMO/CDMO Market Outlook, Scope & Overview:

Industry reports indicate that the global Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) market was valued at USD 18.92 billion in 2022 and is projected to reach USD 41.75 billion by 2030, growing at a CAGR of 10.4% over the forecast period 2023-2030.

Technological Advancements to Drive Growth of Global CMO/CDMO Market

The adoption of advanced manufacturing technologies and increasing outsourcing trends will continue to influence global market revenues. Pharmaceutical and biotechnology companies are increasingly utilizing CMO/CDMO services to optimize production costs, enhance operational efficiency, and focus on core competencies such as drug discovery and development.

As a service segment, biologics manufacturing currently holds a significant share of the global CMO/CDMO market. This segment is anticipated to grow at a year-over-year rate of 10.4% in 2023 over 2022 and reach USD 41.75 billion in revenues by 2030. The increasing demand for biologic drugs, including monoclonal antibodies, vaccines, and cell and gene therapies, is expected to drive market growth.

CMO/CDMO Solutions – Market Dynamics

Drivers:

CMO/CDMO solutions are witnessing significant growth in the global market due to their ability to provide flexible, scalable, and cost-effective manufacturing solutions. The growing pipeline of biologics and complex molecules, coupled with the increasing need for specialized manufacturing capabilities, are key factors driving the adoption of CMO/CDMO services worldwide. Additionally, the rising trend of pharmaceutical outsourcing to mitigate risks, reduce time-to-market, and access advanced technologies is further propelling market growth.

Restraints:

Despite the growth potential, challenges such as stringent regulatory requirements, quality control issues, and the complexity of managing outsourcing relationships are hindering the widespread adoption of CMO/CDMO solutions. Moreover, the high costs associated with biologics manufacturing and the need for extensive technical expertise pose additional challenges to market expansion.

CMO/CDMO Solutions – Market Outlook

The proven benefits of CMO/CDMO solutions in enhancing manufacturing efficiency, reducing operational costs, and accelerating product development timelines have contributed to the market's growth. CMO/CDMO services are expected to witness increased adoption across major markets, including North America, Europe, and Asia Pacific, driven by advancements in manufacturing technologies and the growing emphasis on personalized medicine and biologics production.

Global CMO/CDMO Market

The rise in demand for CMO/CDMO solutions in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global CMO/CDMO market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of CMO/CDMO services, supported by favorable regulatory frameworks and increasing investments in pharmaceutical and biopharmaceutical R&D.

Key Players in the CMO/CDMO Solutions Market

Leading companies in the CMO/CDMO solutions market include Lonza Group, Catalent, Inc., Samsung Biologics, and WuXi AppTec. These companies are at the forefront of developing and commercializing advanced manufacturing and development services for various pharmaceutical and biopharmaceutical applications, including drug substance production, drug product manufacturing, and clinical trial supply.

In conclusion, the global CMO/CDMO market is poised for substantial growth over the forecast period, driven by technological advancements, increasing pharmaceutical outsourcing, and the expanding adoption of biologics and personalized medicine in drug development and manufacturing.

Other Trending Reports

Antidepressants Market Share by Company

Biopharmaceutical Excipients Market Share by Company

Patient Experience Technology Market Share by Company

Cardiac Monitoring Devices Market Share by Company

[marketinsight1234]

Formulation Development Outsourcing Market: Global Industry Analysis and Forecast 2023 – 2030

Global Formulation Development Outsourcing Market was valued at USD 20.15 Billion in 2021 and is expected to reach USD 33.08 Billion by the year 2028, at a CAGR of 7.34%.

The formulation development outsourcing market refers to the practice of pharmaceutical, biotechnology, and other life sciences companies contracting external partners to assist in the development of drug formulations. This process involves the creation and optimization of the composition and delivery systems of pharmaceutical products, ensuring they are safe, effective, and commercially viable. The growing complexity of drug molecules and delivery systems, including biologics and specialized dosage forms, is driving companies to seek specialized expertise and resources outside their organizations. Outsourcing formulation development allows companies to leverage the expertise and infrastructure of contract research organizations (CROs) or contract development and manufacturing organizations (CDMOs), reducing time-to-market and overall development costs. CROs and CDMOs often invest in advanced technologies and equipment for formulation development, providing clients access to specialized capabilities without heavy capital investment.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @

https://introspectivemarketresearch.com/request/15847

Updated Version 2024 is available our Sample Report May Includes the:

Scope For 2024

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports 

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years. 

Leading players involved in the Formulation Development Outsourcing Market include:

Charles River Laboratories International Inc., Aizant Drug Research Solutions Pvt Limited, Catalent Inc., Laboratory Corporation of America Holdings, Biocon Limited (Syngene International), PCI Pharma Services, Hermes Pharma, Pyramid Laboratories Inc and  other Major players. 

If You Have Any Query Formulation Development Outsourcing Market Report, Visit:

https://introspectivemarketresearch.com/inquiry/15847

Segmentation of Formulation Development Outsourcing Market:

By Service

Pre-Formulation Services

Formulation Optimization

By Application

Oncology

Genetic Disorders

Neurology

Infectious Diseases

Respiratory

Cardiovascular

Others

By Dosage Form          

Injectable

Oral

Topical

Other

By Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

What to Expect in Our Report?

(1) A complete section of the Formulation Development Outsourcing market report is dedicated for market dynamics, which include influence factors, market drivers, challenges, opportunities, and trends.

(2) Another broad section of the research study is reserved for regional analysis of the Formulation Development Outsourcing market where important regions and countries are assessed for their growth potential, consumption, market share, and other vital factors indicating their market growth.

(3) Players can use the competitive analysis provided in the report to build new strategies or fine-tune their existing ones to rise above market challenges and increase their share of the Formulation Development Outsourcing market.

(4) The report also discusses competitive situation and trends and sheds light on company expansions and merger and acquisition taking place in the Formulation Development Outsourcing market. Moreover, it brings to light the market concentration rate and market shares of top three and five players.

(5) Readers are provided with findings and conclusion of the research study provided in the Formulation Development Outsourcing Market report.

Our study encompasses major growth determinants and drivers, along with extensive segmentation areas. Through in-depth analysis of supply and sales channels, including upstream and downstream fundamentals, we present a complete market ecosystem.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Acquire This Reports: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=15847

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assisting our clients to grow and have a successful impact on the market. Our team at IMR is ready to assist our clients to flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, that specializes in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyse extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1047

Email: sales@introspectivemarketresearch.com

[blog-site-for-market-research]

Market Report: Delving into the Pharmaceutical Analytical Testing Outsourcing Market Size and Share

Market Overview –

The Pharmaceutical Analytical Testing Outsourcing Market refers to the sector within the pharmaceutical industry where companies outsource their analytical testing needs to specialized service providers. This market has witnessed significant growth in recent years due to the increasing complexity of drug formulations and the stringent regulatory requirements imposed by health authorities worldwide.

Outsourcing Analytical Testing in the pharmaceutical industry is witnessing significant traction as companies seek cost-effective and specialized solutions. Outsourcing firms offer expertise in analytical testing, ensuring regulatory compliance and quality assurance. This trend is driven by the complexity of testing requirements and the need for efficient resource allocation. The market for outsourcing analytical testing services is expected to continue growing as pharmaceutical companies prioritize core activities and seek external expertise.

Companies outsource analytical testing to gain access to state-of-the-art facilities, expertise, and specialized technologies without the need for heavy investments in infrastructure and personnel training. This trend is particularly pronounced among smaller pharmaceutical companies and startups with limited resources.

Key players in the Pharmaceutical Analytical Testing Outsourcing Market include contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and independent analytical laboratories. These entities offer a wide range of services, including method development and validation, stability testing, raw material testing, and quality control testing.

Factors driving the growth of this market include the increasing globalization of the pharmaceutical industry, the rising demand for specialized analytical techniques such as mass spectrometry and chromatography, and the growing emphasis on outsourcing non-core activities to focus on core competencies.

Despite the opportunities, the market faces challenges such as data security concerns, quality control issues, and the need for regulatory compliance. However, with the right strategies in place, the Pharmaceutical Analytical Testing Outsourcing Market is poised for continued growth and innovation in the coming years.

In 2022, the pharmaceutical analytical testing outsourcing market was estimated to be worth USD 4.2 billion. According to projections, the pharmaceutical analytical testing outsourcing market is expected to increase at a compound annual growth rate (CAGR) of 8.70% from USD 4.6 billion in 2023 to USD 7.5 billion by 2030.

Segmentation –

The global pharmaceutical analytical testing outsourcing market, by product type, has been segmented into finished products, active pharmaceutical ingredients, and raw materials. The finished products segment accounted for a value of USD 2,055.4 million in 2017. The market, by services, can be segmented into bioanalytical testing, method development & validation, stability testing, and others. On the basis of end user, the global pharmaceutical analytical testing outsourcing market is segmented into pharmaceutical & biopharmaceutical companies and biotechnology industry.

Regional Analysis –

The Pharmaceutical Analytical Testing Outsourcing Market exhibits diverse regional trends influenced by factors such as regulatory frameworks, technological advancements, and the presence of outsourcing service providers.

North America dominates the market, driven by stringent regulatory requirements, a robust pharmaceutical industry, and a high demand for outsourcing services to ensure compliance and product quality. The region also benefits from a mature outsourcing ecosystem and a strong network of contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Similarly, Europe holds a significant market share, supported by a well-established pharmaceutical sector, favorable regulatory environment, and increasing emphasis on cost-effective solutions.

In Asia Pacific, the market is witnessing rapid growth fueled by the outsourcing trend among pharmaceutical companies, expanding healthcare infrastructure, and a skilled workforce at competitive costs. Latin America and the Middle East & Africa regions present opportunities for market expansion, driven by the growing pharmaceutical industry, improving regulatory landscape, and cost advantages. However, challenges such as quality control issues and intellectual property concerns may impact market growth in these regions. Overall, the Pharmaceutical Analytical Testing Outsourcing Market showcases a dynamic landscape across different regions, characterized by varying regulatory environments, outsourcing capabilities, and market demands.

Key Players –

Pharmaceutical analytical testing outsourcing companies include Boston Analytical (New Hampshire), West Pharmaceutical Services, Inc. (U.S.), Exova Group PLC (U.K.), Source BioScience (U.K.), Pace Analytical Services, Inc. (U.S.), Merck KGaA (Germany), WuXi AppTec (U.S.), Toxikon (U.S.), Eurofins Scientific (Belgium and Luxembourg), Intertek Group Plc (U.K.), Charles River Laboratories International, Inc (U.S.), SGS SA (U.K.), and Pharmaceutical Product Development, LLC (U.S.).

Related Reports –

Neurostimulation Devices

Crohn’s Disease

Healthcare Biometrics

Osteoporosis Drugs

For more information visit at MarketResearchFuture

[delicatemagazinedreamer]

Global Contract Pharmaceutical Manufacturing Market Is Estimated To Witness High Growth Owing To Increasing Demand for Outsourcing and Technological Advancements

The global Contract Pharmaceutical Manufacturing Market is estimated to be valued at US$ 178.94 billion in 2022 and is expected to exhibit a CAGR of 9.3% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:

The Contract Pharmaceutical Manufacturing Market refers to the outsourcing of pharmaceutical manufacturing processes to third-party organizations. This enables pharmaceutical companies to focus on their core competencies while reducing costs, increasing efficiency, and gaining access to specialized expertise and facilities. Contract pharmaceutical manufacturers provide a wide range of services including formulation development, manufacturing, packaging, labeling, and distribution. They also adhere to strict regulatory guidelines to ensure quality and safety of the products.

B) Market Dynamics:

The market dynamics of the contract pharmaceutical manufacturing industry are driven by two main factors: increasing demand for outsourcing and technological advancements.

1) Increasing Demand for Outsourcing:

Pharmaceutical companies are increasingly outsourcing their manufacturing processes to contract manufacturers due to various advantages. Outsourcing allows companies to reduce capital expenditures, minimize operational risks, and focus on research, development, and marketing activities. Contract manufacturers offer specialized expertise, state-of-the-art facilities, and technology platforms that help in optimizing production processes and improving product quality. Moreover, outsourcing enables pharmaceutical companies to access a global network of manufacturing facilities, making it easier to penetrate new markets.

2) Technological Advancements:

Technological advancements have revolutionized the contract pharmaceutical manufacturing industry. Automation and robotics have significantly improved production efficiency by reducing errors and increasing throughput. Advanced analytical techniques such as spectroscopy, chromatography, and mass spectrometry have enhanced quality control processes. Moreover, the adoption of cloud computing and real-time data sharing has improved communication and collaboration between pharmaceutical companies and contract manufacturers, leading to faster project execution and reduced lead times.

C) Market Key Trends:

One key trend in the Contract Pharmaceutical Manufacturing Market is the increasing adoption of contract development and manufacturing organization (CDMO) services. CDMOs offer end-to-end solutions, including drug discovery, formulation development, clinical trials, and commercial scale manufacturing. Pharmaceutical companies are opting for CDMOs to streamline their operations and reduce the time and cost associated with multiple vendor management.

Another key trend is the growing demand for biologics manufacturing services. Biologics, such as monoclonal antibodies, vaccines, and cell therapies, require specialized manufacturing processes. Contract manufacturers with expertise in biologics manufacturing are in high demand due to the increasing prevalence of complex diseases and advancements in biotechnology.

D) SWOT Analysis:

- Strength: Strong global outsourcing trend and cost-saving potential.

- Weakness: Dependency on contract manufacturers for quality control and compliance.

- Opportunity: Increasing demand for personalized medicine and niche therapies.

- Threats: Stringent regulatory requirements and potential risk of intellectual property infringement.

E) Key Takeaways:

- The global contract pharmaceutical manufacturing market is expected to witness high growth, exhibiting a CAGR of 9.3% over the forecast period. This growth is driven by the increasing demand for outsourcing and technological advancements.

- North America is expected to dominate the market due to a well-established pharmaceutical industry, favorable regulatory environment, and high adoption of outsourcing.

- Key players operating in the global contract pharmaceutical manufacturing market include Accenture plc, Cognizant Technology Solutions, ATOS SE, Catalent, Inc., Covance, Inc., Boehringer Ingelheim GmbH, Genpact Limited, Lonza Group, PAREXEL International Corporation, Quintiles Transnational Corporation, Abbvie, Inc., Baxter International Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma, Pfizer, Inc., The Almac Group, Teva Pharmaceutical Industries Ltd., and Piramal Enterprises Ltd.

In conclusion, the contract pharmaceutical manufacturing market is witnessing significant growth due to the increasing trend of outsourcing and technological advancements. The market offers opportunities for pharmaceutical companies to optimize their operations, reduce costs, and access specialized expertise and facilities. However, stringent regulatory requirements and intellectual property concerns pose challenges to the market's growth. Overall, the market is poised for substantial development in the coming years.

[esglatestmarketnews]

Biopharmaceutical CMO & CRO Production Capacity Study—a Deep-dive on Firms Opting for Contract Services

CMOs are exploring the potential of mammalian cell culture production amidst soaring demand for biopharmaceutical contract manufacturing services. Incumbents, such as Charles River and Lonza have furthered investments in mammalian cells. To illustrate, in May 2021, Lonza announced pouring USD 936 million to bolster the footprint of mammalian drug substance manufacturing sites in the U.S. and Switzerland. 

Biopharmaceutical firms are responding to the demand for outsourced services with bullish investments in research activities. For instance, in July 2022, Wuxi Biologics contemplated expanding its large-scale drug product & drug substance manufacturing capabilities and R&D in Singapore.

Adoption of Contract Development & Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) with surging demand for Monoclonal Antibodies (MAbs) products will boost the market share. The final report, along with the database, will peruse the following dynamics:

• Insights on commercial availability and annual approvals of MAb products.

• Commercially available biopharmaceuticals and biologics produced using mammalian cell lines.

• Competitive landscape with industry developments.

• CMO Mapping of 88 companies.

Get your copy or request a free sample of the report “Biopharmaceutical CMO & CRO Production Capacity Study,” compiled and published by Grand View Research. 

Biopharmaceutical CMO & CRO Production Capacity Report Scope

CMO Capacity mapping (for 88 companies)

Key Players: Location Mapping & existing Capacities

Recent expansions/ Future plans

Comparative Heat Map

Get more insights from our in-depth market intelligence report, “Biopharmaceutical CMO And CRO Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Service (Contract Manufacturing, Contract Research), By Product, And Segment Forecasts, 2023 – 2030.”

About Us

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.

Find More information @ https://www.grandviewresearch.com/info/trend-reports

[rootsanalysis]

CHALLENGES AND OPPORTUNITIES FOR CELL LINE DEVELOPMENT AND CHARACTERIZATION SERVICE PROVIDERS

In the past few years, there has been a significant surge in the demand for recombinant proteins and cellular systems for biomedical research, diagnostics and different therapies. In order to support the large- scale production and manufacturing of such cell- based products, there is an imperative need for the efficient development of high- quality stable cell lines. In fact, 60-70% of manufacturing processes of available biologics require live mammalian systems. A cell line refers to a defined population of cells that originates from a single common ancestor cell and have the ability to retain stable phenotypes and functions.  In general, once the primary culture is sub-cultured, it becomes a cell line.

 To request a sample copy / brochure of this report, please visit : https://www.rootsanalysis.com/reports/cell-line-development-and-characterization-services/request-sample.html

 Cell lines have revolutionized scientific R&D and are currently being used for a myriad of applications.

 The development and characterization of cell lines is both technically challenging and financially demanding. It requires cost intensive materials, specialized genetic engineering technologies, aseptic cell culturing conditions, specialized infrastructure for cell storage, and product-specific analytical techniques for cell / cell line testing. Recent years have witnessed the emergence of a large number of highly qualified contract research organizations (CROs), contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) that assist drug developers and researchers, and offer the following benefits:

§  Reduction of economic burden: Cost of developing and characterizing cell lines may vary between few thousand dollars to hundreds of thousands of dollars, depending on the cell line engineering methods, expression hosts, upstream and downstream process development and the type of tests required during research and / or the production phases. For instance, cell lines edited using CRISPR/Cas9 system are likely to be priced higher. Service providers have the potential to reduce the financial risk for the stakeholders that do not have the capacity, capability or the in-house expertise to carry out such operations.

§  Enables companies to focus on research: Contract service providers offer a variety of services for different cell lines, allowing developers and researchers to avail analytical tests as per their requirements. Therefore, outsourcing cell line development and characterization operations allows product developers to focus their efforts on R&D activities.

§  Knowledge expertise: Service providers have the necessary skillset to carry out complicated procedures in minimum time with reduced chances of failure. In addition, these organizations often provide consulting services to assist researchers to obtain accurate results and address regulatory concerns.

§  Risk Sharing: One of the crucial factors determining the net outcome of any industrial process is risk-analysis. Outsourcing few of the components of an industrial process is just like shifting certain responsibilities to the outsourced vendor. Henceforth, it is a mutual understanding between the companies to handle the risk factors in a better way.

§  Integrated offerings: Nowadays, contract services providers are offering full range services, from cell line generation to screening and characterization, including the establishment and maintenance of master cell banks (MCBs) and working cell banks (WBCs), along with the end-product formation from cell lines.

Despite the increasing opportunity in this domain, high entry costs (associated with building the required technical expertise and setting up of facilities) and rising regulatory stringencies, are the primary impediments to the number of stakeholders entering this market. For sponsors looking to outsource, there are multiple areas of concern associated with engaging service provider entities; some of the prominent challenges faced, include lack of necessary expertise for substandard cell growth troubleshooting, and process transfer related complexities. The selection of an inappropriate service provider partner can prove to be disastrous in the long run, creating issues, such as delays and cost overruns.  

 Despite the aforementioned challenges, the growing demand for novel biologics, especially amidst COVID-19 pandemic, impending patent expiries of several blockbuster biologics, growing popularity of regenerative medicines and cellular vaccines, and advancements in genetic engineering and bioanalytical technologies, are some of the major factors that are anticipated to drive the growth of cell line development and characterization services market, in the mid to long term.

 Key Questions Answered

Who are the leading players offering     cell line development services?

What kind of CDMO support is     available for cell line development, across different regions?

What are the common sources, gene     delivery methods, protein yield and affiliated services offered by the     cell line development service providers?

Who are the leading industry and     non-industry players offering cell line     characterization services?

What are the most popular services     offered for characterization of cell lines?

Which partnership models are     commonly adopted by stakeholders in this industry?

How is the current and future     opportunity likely to be distributed across key market segments?

What are the anticipated future     trends related to cell line development and characterization market?

 For additional details, please visit : https://www.rootsanalysis.com/reports/cell-line-development-and-characterization-services.html

  You may also be interested in the following titles:

1.      RAS Targeting Therapies Market, 2021-2031

2.      Novel T-Cell Immunotherapies Market, 2021-2030

3.      HER2 Targeting Therapies Market, 2021-2030

  About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

[metiresearchinfo]

Pharmaceutical Contract Development and Manufacturing Market By Service [Pharmaceutical Manufacturing Services (API, FDF), Drug Development Services, Biologics Development], End User [Big & Generic Pharmaceutical Companies] – Global Forecast to 2027

The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 6.5% from 2020 to 2027 to reach $134.23 billion by 2027. The complex structure for manufacturing pharmaceuticals, increasing investments in pharmaceutical R&D, growing outsourcing of clinical trials, and the outbreak of the COVID-19 pandemic are some of the major drivers for the growth of this market. In addition, the rising demand for generic medicines & biologics, growing demand for cell & gene therapies, and increasing pharmaceutical outsourcing support the growth of this market. However, service quality & IPR issues, lack of skilled professionals, and introduction of serialization are the factors expected to hinder the growth of the pharmaceutical contract development and manufacturing market during the forecast period.  

COVID-19 Impact on the Pharmaceutical Contract Development and Manufacturing Market      

The recent outbreak of COVID-19 has impacted the healthcare market. The pharmaceutical contract development and manufacturing industry has experienced a positive impact due to this pandemic. The outbreak has catalyzed the demand for pharmaceuticals and has stirred the development of corona-related vaccines, antiviral vaccines, antibody therapy, and various pharmaceutical products. This has urged pharmaceutical organizations to hire contract development and manufacturing organizations for pharmaceutical drug development & manufacturing to sustain their business.

The demand for both high quality and high volume CGMP drug substance and drug product manufacturing services has soared, particularly for CDMOs able to support a wide range of COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

Most pharmaceutical companies, CROs, and research institutes are working together to translate research into effective pharmaceutical products. For instance, in August 2020, Catalent Inc. (U.S.) signed an agreement with AstraZeneca PLC (U.K.) to expand manufacturing support for the University of Oxford’s adenovirus vector-based COVID-19 vaccine AZD1222. In September 2020, Thermo Fisher Scientific Inc. (U.S.) partnered with Inovio Pharmaceuticals, Inc. (U.S.) to manufacture INOVIO's DNA COVID-19 vaccine candidate INO-4800 and to enhance the commercial production of INO-4800.

                                                              Click here to: Get Free Sample Pages of this Report

Increasing investments in the pharmaceutical R&D support the market growth

The pharmaceutical industry is largely driven by scientific discovery and development, in conjunction with toxicological and clinical experience. Also, healthcare R&D activities have significantly increased with rising funding from various government organizations. This funding is mainly driven by rising health care concerns, complexities in clinical trials, and drug failure in early-phase studies.

Governments in developed and developing nations are offering to fund the propagation of biotechnology and biopharmaceutical research. For instance, the Indian government launched 'Pharma Vision 2020' to increase the production capacities of biopharmaceuticals by reducing the approval time for new facilities. Also, the government decided in favor of 100% foreign direct investment in the pharmaceutical industry, which is expected to increase investments in R&D activities. Similarly, in the U.S., the National Institute of Health (NIH) collaborated with 11 biopharmaceutical companies to launch the Partnership for Accelerating Cancer Therapies (PACT) to develop immunotherapy for cancers. The program involved a total investment of USD 215 million.

Further, pharmaceutical companies have also increased their spending on R&D. The extent of pharmaceutical R&D spending serves as an important metric to show a company’s commitment to finding new drugs. At present, the global pharmaceutical industry has the second-highest R&D intensity, i.e. expenditure as a share of any sector's sales measures. Thus, the increasing investments from the government for pharmaceutical R&D is likely to boost outsourcing, thereby accelerating pharmaceutical contract development & manufacturing market growth.

Growing consolidation in the market, an ongoing trend

Due to growing pressure on leading pharmaceutical players, complex drug development process, growing number of patents expiring, increasing R&D costs, and the increasing prevalence of chronic diseases are some of the factors making outsourcing essential.

CDMOs offer the convenience of time and cost due to the inherent nature of dealing with a single entity. The relationship also creates opportunities for the pharmaceutical CDMOs to sell more services to the same customer and locking in products at earlier stages of their life cycles.

Due to the growing pressure on the industry’s leading players to follow stringent regulatory timelines and lack of human clinical trial data, pharmaceutical giants are entering into collaborations, partnerships, and agreements to jointly broaden their services offered across all drug development & pharmaceutical manufacturing processes:

In June 2020, Catalent Inc. (U.S.) collaborated with Moderna, Inc. (U.S.) for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273).

In April 2020, ICON plc (Ireland) agreed with Pfizer Inc. (U.S.) to supply drug and device development and commercialization services.

                                              Click here to: Get a Free Request Sample Copy of this report

Key Findings in the Pharmaceutical Contract Development and Manufacturing Market Study:

Pharmaceutical manufacturing services generated a large proportion of revenue compared to other services

The large share of this segment is mainly attributed to the use of advanced technologies & manufacturing skills, the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs.

Pharmaceutical API contract manufacturing services are estimated to account for the largest share of the pharmaceutical contract manufacturing services market in 2020

The need for the reduction in the cost of production of APIs, growing number of initiatives undertaken by pharmaceutical companies, increasing investments in API manufacturing services, and growing need to reduce the time required for the drug development process are expected to drive the growth of the pharmaceutical API contract manufacturing services segment.

In 2020, the big pharmaceutical companies segment to dominate pharmaceutical contract development and manufacturing market

The major share of this segment is primarily attributed to the growing prevalence of various infectious diseases, growing need for state-of-the-art processes & production technologies, and the rising cost of clinical trials and early development studies.

Asia-Pacific: Fastest growing regional market

In 2020, North America is estimated to command the largest share of the pharmaceutical contract development and manufacturing market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia-Pacific will be the fastest-growing regional market due to the growing manufacturing sector, favorable government regulations, increasing emphasis on off-patent drugs, and highly skilled workforce in the region. In addition, the increase in outsourcing activities in countries like India and China due to lower costs and availability of qualified healthcare professionals are the other key factors propelling the growth of the Asia-Pacific pharmaceutical contract development and manufacturing market.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past four years. The key players profiled in the pharmaceutical contract development and manufacturing market report are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.),  PPD Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma-Fertigung GmbH & Co. KG  (Germany), AbbVie Inc. (U.S.), Synoes Health, Inc. (U.S.), Piramal Enterprises Limited (India), Almac Group (U.K.), Albany Molecular Research Inc. (U.S.), Fareva Holding SA (France), and Jubilant Life Sciences Limited (India).

Scope of the Report:

Pharmaceutical Contract Development and Manufacturing Market, by Service

Pharmaceutical Manufacturing Services

Drug Development Services

Biologics Manufacturing Services

Pharmaceutical API Manufacturing Services

Pharmaceutical FDF Manufacturing Services

Parenteral/Injectable Manufacturing Services

Tablet Manufacturing Services

Capsule Manufacturing Services

Oral Liquid Manufacturing Services

Other Formulations Manufacturing Services

Biologics API Manufacturing Services

Biologics API Manufacturing Services

Pharmaceutical Contract Development and Manufacturing Market, by End User

Big Pharmaceutical Companies

Small and Med-Size Pharmaceutical Companies

Generic Pharmaceutical Companies

Pharmaceutical Contract Development and Manufacturing Market, by Geography

North America

Europe

Asia-Pacific (APAC)

Latin America

Middle East & Africa

U.S.

Canada

Germany

U.K.

France

Italy

Spain

Rest of Europe (RoE)

China

Japan

India

Rest of APAC (RoAPAC)

[theonpharma]

The Future of Contract Manufacturing in the Pharmaceutical Industry

How Contract Manufacturing Look Like in Pharma?

Many productions can be outsourced to contract manufacturers (CMs) for businesses to continue providing quality products to their customers in a cost-effective manner, allowing them to focus on other aspects of their business, increasing overall productivity and efficiency, and improving their bottom line.

Because of the COVID-19 pandemic, the pharmaceutical industry sought out contract manufacturing in droves. Its increase from US$934.8 billion in 2017 to $1.17 trillion in 2021 demonstrates the industry’s exponential growth, though actual figures could be much higher due to better healthcare becoming a global priority in 2020.

Pharma has been burdened with high financial performance to keep up with demand, particularly when purchasing and operating expensive equipment for pharmaceutical mass production. To combat this, many businesses have begun outsourcing their manufacturing to contract manufacturers (CMs) who have the necessary equipment, facilities, and labor force to carry out more cost-effective production. This type of outsourcing is revolutionary.

Six Contract Manufacturing Trends to Watch in the Future Collaboration with the proper contract manufacturer is becoming a practical trend among businesses, especially as CMs continue developing and expanding their own services to keep up with ever-changing global markets.

Here are six developments in contract manufacturing for the pharmaceutical industry that we anticipate:

1. Improving performance through improved artificial intelligence and electronic platforms (e-platforms) Many CMs incorporate artificial intelligence and other technological innovations to become more cost-effective and reduce production time. The digitization of pharmaceutical Contract Development and Manufacturing Organizations (CDMOs/CMOS) services will result in greater efficiency in delivering products to target customers.

Data suggests that sophisticated technologies, such as machine learning to identify digital images of cells or automated data gathering and analysis to find answers to complicated diseases like Alzheimer’s, are driving the pharma industry’s growth. Similarly, pharmaceutical contract manufacturers are continually developing AI technologies to increase risk identification and, as a result, pharmaceutical product quality and safety.

2. Remote tracing in real-time Pharmaceutical companies typically audit or supervise their CM’s production and delivery processes to monitor the manufacturing process. However, as contract manufacturers improve their processes, they can monitor product conditions remotely.

This type of real-time tracking is made possible by the Internet of Things (IoT), which enables pharmaceutical supply chain companies to share data and respond quickly to any issues. As a result, the pharma industry will better oversee the manufacturing process and supply chain and more accurately orchestrate outcomes.

3. Supply chain channels that are secure Despite its apparent advantages, electronic communication may jeopardize contract manufacturing’s future. If an internet database is compromised or the formula is delivered through unprotected methods, a patented vaccine formula, for example, can be stolen. As a result, serialization laws are already in place to protect critical data.

Third-party manufacturers typically employ systems that protect production blueprints and sensitive information from malicious entities. This leads us to the next trend in contract manufacturing: blockchain.

4. The introduction of blockchain Another way contract manufacturing models make technological features more secure is by implementing blockchain and other high-level cybersecurity mechanisms. Blockchain is proving to be a valuable business asset in the pharmaceutical industry due to its broad range of applications, all of which are safeguarded by cutting-edge cryptography technology.

Companies in the pharmaceutical supply chain, such as CMs and pharmaceutical companies, will be able to scan and record barcodes along the way using blockchain’s ledger system, producing an audit trail that can be followed by all parties involved. Sensors can be integrated into the supply chain with blockchain, and characteristics like temperature and humidity may be recorded in the ledger system, which is especially crucial for temperature-sensitive drugs like insulin.

In this way, blockchain secures and streamlines the pharmaceutical supply chain by allowing everyone involved to track the medicine’s journey at every stage. This not only makes the operation run more smoothly, but it also aids in proving the authenticity of a drug. Pharmaceutical companies that work with CMs can ensure that their product is handled and distributed safely by implementing this feature.

5. Services tailored to specific niches Developing precision or personalized medicines for small batch productions is a service that we see CMOs in the pharmaceutical industry readily accommodating. This is being aided by the development of new equipment capable of producing small batches of goods quickly.

Precision or personalized medicines end ‘one size fits all’ treatment options for people suffering from specific illnesses or diseases. The pharmaceutical manufacturing process must adapt to small batch sizes to meet these medical requirements.

This also has the advantage of allowing pharmaceutical products to be manufactured and distributed with greater urgency, such as when a last-minute order is required for an out-of-stock medicine in a specific location. Diseases appear out of nowhere in some cases, such as Ebola outbreaks in Africa, and the minimum demand for a medicine varies depending on the case. This necessitates continuous backup production and the ability to produce small batches to avoid the risks of expired medicines.

Late-stage personalization The final advancement in contract manufacturing for pharmaceuticals is late-stage customization, which occurs when a specific good is only pre-assembled, implying that it can be processed at any time depending on market demand.

This reduces the possibility of errors and creates a more efficient production process by freeing up storage space and requiring fewer stored materials. However, the most significant advantage of late-stage customization is ensuring that all labels and packaging are by current legislation.

This is especially important in the pharmaceutical industry, where serialization legislation protects against counterfeit drugs. With more pharmaceutical CMs offering late-stage customization, labels and packaging can be tweaked right up to the last second with variable data, depending on the market, region, or customer to whom the medicine is supplied. This ensures that all pharmaceutical labels and packaging are updated with the latest regulations.

[wiseguyreport1222]

Millimeter Wave Frequency Sources and Related Components EUROPE Market Research Report 2021-2026

The Millimeter Wave Frequency Sources and Related Components market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

ALSO READ:  http://www.marketwatch.com/story/millimeter-wave-frequency-sources-and-related-components-market-research-report-with-size-share-value-cagr-outlook-analysis-latest-updates-data-and-news-2021-2028-2021-07-13

Market segmentation Millimeter Wave Frequency Sources and Related Components market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers 24–57 GHz 57–95 GHz 95–300 GHz

Market segment by Application, can be divided into Mobile & Telecom Consumer & Commercial Healthcare Industrial Automotive & Transportation Imaging

ALSO READ:  http://www.marketwatch.com/story/contract-development-manufacturing-organization-cdmo-outsourcing-market-research-report-with-size-share-value-cagr-outlook-analysis-latest-updates-data-and-news-2021-2028-2021-07-23

Market segment by players, this report covers Smiths Group Eravant Aviat Networks Farran Technologies Millimeter Wave Products Axxcss Wireless Solutions NEC Corporation Siklu L3HARRIS

Market segment by regions, regional analysis covers North America (United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, Italy, and Rest of Europe) Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific) South America (Brazil, Argentina, Rest of South America) Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

ALSO READ:  http://www.marketwatch.com/story/glass-fiber-reinforced-polymer-market-research-report-with-size-share-value-cagr-outlook-analysis-latest-updates-data-and-news-2021-2028-2021-07-21

The content of the study subjects, includes a total of 12 chapters: Chapter 1, to describe Millimeter Wave Frequency Sources and Related Components product scope, market overview, market opportunities, market driving force and market risks. Chapter 2, to profile the top players of Millimeter Wave Frequency Sources and Related Components, with revenue, gross margin and global market share of Millimeter Wave Frequency Sources and Related Components from 2019 to 2021. Chapter 3, the Millimeter Wave Frequency Sources and Related Components competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast. Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026. Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Millimeter Wave Frequency Sources and Related Components market forecast, by regions, type and application, with revenue, from 2021 to 2026. Chapter 11 and 12, to describe Millimeter Wave Frequency Sources and Related Components research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview 1.1 Product Overview and Scope of Millimeter Wave Frequency Sources and Related Components 1.2 Classification of Millimeter Wave Frequency Sources and Related Components by Type 1.2.1 Overview: Global Millimeter Wave Frequency Sources and Related Components Market Size by Type: 2020 Versus 2021 Versus 2026 1.2.2 Global Millimeter Wave Frequency Sources and Related Components Revenue Market Share by Type in 2020 1.2.3 24–57 GHz 1.2.4 57–95 GHz 1.2.5 95–300 GHz 1.3 Global Millimeter Wave Frequency Sources and Related Components Market by Application 1.3.1 Overview: Global Millimeter Wave Frequency Sources and Related Components Market Size by Application: 2020 Versus 2021 Versus 2026 1.3.2 Mobile & Telecom 1.3.3 Consumer & Commercial 1.3.4 Healthcare 1.3.5 Industrial 1.3.6 Automotive & Transportation 1.3.7 Imaging 1.4 Global Millimeter Wave Frequency Sources and Related Components Market Size & Forecast 1.5 Global Millimeter Wave Frequency Sources and Related Components Market Size and Forecast by Region 1.5.1 Global Millimeter Wave Frequency Sources and Related Components Market Size by Region: 2016 VS 2021 VS 2026 1.5.2 Global Millimeter Wave Frequency Sources and Related Components Market Size by Region, (2016-2021) 1.5.3 North America Millimeter Wave Frequency Sources and Related Components Market Size and Prospect (2016-2026) 1.5.4 Europe Millimeter Wave Frequency Sources and Related Components Market Size and Prospect (2016-2026) 1.5.5 Asia-Pacific Millimeter Wave Frequency Sources and Related Components Market Size and Prospect (2016-2026) 1.5.6 South America Millimeter Wave Frequency Sources and Related Components Market Size and Prospect (2016-2026) 1.5.7 Middle East and Africa Millimeter Wave Frequency Sources and Related Components Market Size and Prospect (2016-2026) 1.6 Market Drivers, Restraints and Trends 1.6.1 Millimeter Wave Frequency Sources and Related Components Market Drivers 1.6.2 Millimeter Wave Frequency Sources and Related Components Market Restraints 1.6.3 Millimeter Wave Frequency Sources and Related Components Trends Analysis 2 Company Profiles 2.1 Smiths Group 2.1.1 Smiths Group Details 2.1.2 Smiths Group Major Business 2.1.3 Smiths Group Millimeter Wave Frequency Sources and Related Components Product and Solutions 2.1.4 Smiths Group Millimeter Wave Frequency Sources and Related Components Revenue, Gross Margin and Market Share (2019-2021) 2.1.5 Smiths Group Recent Developments and Future Plans 2.2 Eravant 2.2.1 Eravant Details 2.2.2 Eravant Major Business 2.2.3 Eravant Millimeter Wave Frequency Sources and Related Components Product and Solutions 2.2.4 Eravant Millimeter Wave Frequency Sources and Related Components Revenue, Gross Margin and Market Share (2019-2021) 2.2.5 Eravant Recent Developments and Future Plans 2.3 Aviat Networks 2.3.1 Aviat Networks Details 2.3.2 Aviat Networks Major Business 2.3.3 Aviat Networks Millimeter Wave Frequency Sources and Related Components Product and Solutions 2.3.4 Aviat Networks Millimeter Wave Frequency Sources and Related Components Revenue, Gross Margin and Market Share (2019-2021) 2.3.5 Aviat Networks Recent Developments and Future Plans 2.4 Farran Technologies 2.4.1 Farran Technologies Details 2.4.2 Farran Technologies Major Business 2.4.3 Farran Technologies Millimeter Wave Frequency Sources and Related Components Product and Solutions 2.4.4 Farran Technologies Millimeter Wave Frequency Sources and Related Components Revenue, Gross Margin and Market Share (2019-2021) 2.4.5 Farran Technologies Recent Developments and Future Plans 2.5 Millimeter Wave Products 2.5.1 Millimeter Wave Products Details 2.5.2 Millimeter Wave Products Major Business 2.5.3 Millimeter Wave Products Millimeter Wave Frequency Sources and Related Components Product and Solutions 2.5.4 Millimeter Wave Products Millimeter Wave Frequency Sources and Related Components Revenue, Gross Margin and Market Share (2019-2021) 2.5.5 Millimeter Wave Products Recent Developments and Future Plans 2.6 Axxcss Wireless Solutions 2.6.1 Axxcss Wireless Solutions Details 2.6.2 Axxcss Wireless Solutions Major Business 2.6.3 Axxcss Wireless Solutions Millimeter Wave Frequency Sources and Related Components Product and Solutions 2.6.4 Axxcss Wireless Solutions Millimeter Wave Frequency Sources and Related Components Revenue, Gross Margin and Market Share (2019-2021) 2.6.5 Axxcss Wireless Solutions Recent Developments and Future Plans 2.7 NEC Corporation 2.7.1 NEC Corporation Details 2.7.2 NEC Corporation Major Business 2.7.3 NEC Corporation Millimeter Wave Frequency Sources and Related Components Product and Solutions 2.7.4 NEC Corporation Millimeter Wave Frequency Sources and Related Components Revenue, Gross Margin and Market Share (2019-2021) 2.7.5 NEC Corporation Recent Developments and Future Plans 2.8 Siklu 2.8.1 Siklu Details 2.8.2 Siklu Major Business 2.8.3 Siklu Millimeter Wave Frequency Sources and Related Components Product and Solutions 2.8.4 Siklu Millimeter Wave Frequency Sources and Related Components Revenue, Gross Margin and Market Share (2019-2021)

….CONTINUED

CONTACT DETAILS :

sales@wiseguyreports.com

+44 203 500 2763

+1 62 825 80070

971 0503084105

[decisionforsight]

Global Drug Discovery Outsourcing Market

Global Drug Discovery Outsourcing Market Size, Share, Growth, Industry Trends and Forecast 2020-2030

Drug discovery outsourcing is a process of inventing a new medicine in the field of pharmaceuticals, biotechnology, and pharmacology. Drug discovery is a very time consuming, complex, and expensive process and sometimes may have a low success rate. Usually, small pharmaceutical companies develop new drug molecules and sell the patent rights to big companies who can afford to conduct clinical trials and observe whether the drugs are suitable or not. Companies outsource their drug discovery process in order to focus on their core competencies like manufacturing, marketing, and product labelling. The companies providing outsourcing services for drug discovery are established companies with developed infrastructure, developed technological front, and skilled expertise. The global drug discovery outsourcing market is accounted approximate USD 2.5 billion in 2020 and it is expected to reach approximate USD 5.5 billion by 2030 with a CAGR of 8.3% during forecast period.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.decisionforesight.com/request-sample/DFS020188

Market Dynamics and Factors:

Rapid progression in technology, reduced approval time, and increasing strategic collaborations in the field of drug development are some of the major factors driving the growth of the drug discovery outsourcing market. For instance, AstraZeneca established multiple outsourcing partnerships with Cancer Research U.K, Cambridge Institute, University of Texas MD Anderson Cancer Centre, Medical Research Council Laboratory of Molecular Biology, and Academic Drug Discovery Consortium in 2014. Cost reduction, access to specialised knowledge and technology, and greater innovation are the major reasons because of which top pharmaceutical companies are opting for outsourcing their drug discovery process. Advancements in emerging technologies such as artificial intelligence and its implementation in drug discovery has also contributed towards the market growth. However, certain restraining factors like high price of drug discovery outsourcing, and increasing risk of drug failure are hindering the growth of the drug discovery outsourcing market. 

Market Segmentation:

Global Drug Discovery Outsourcing Market – By Workflow

Target Identification & Screening

Target Validation & Functional Informatics

Lead Identification & Candidate Optimization

Preclinical Development

Others

Global Drug Discovery Outsourcing Market – By Therapeutics Area

Respiratory System

Pain & Anesthesia

Oncology

Ophthalmology

Hematology

Cardiovascular

Endocrine

Gastrointestinal

Immunomodulation

Dermatology

Anti-Infective

Central Nervous System

Genitourinary System

Global Drug Discovery Outsourcing Market – By Drug Type

Small Molecules

Large Molecules

Global Drug Discovery Outsourcing Market – By Geography

North America

U.S.

Canada

Mexico

Europe

U.K.

France

Germany

Italy

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

Rest of Asia Pacific

ROW

Latin America

Middle East

Africa

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC at @ https://www.decisionforesight.com/toc-request/DFS020188

Geographic Analysis:

North America is expected to dominate the global drug discovery outsourcing market during the forecast period in terms of market share. The presence of a well-established research infrastructure; existence of a large pool of key players of the pharmaceutical industry; greater adoption of technological advancements; and huge investments in drug discovery research & development are some of the major factors attributing to the market dominance of the region. The Asia Pacific region is anticipated to be the fastest growing market during the forecast period. The growing number of clinical research organisations (CRO), contract manufacturing organisations (CMO), and contract development and manufacturing organisations (CDMO) in the region has resulted in huge trend of outsourcing manufacturing and R&D activities to China and India. This has fuelled the growth of the drug discovery outsourcing market in the APAC region. Government initiatives in the APAC nations to forge ties with U.S pharmaceutical companies is going to propel the market growth in the future. For instance, China launched the Market Authorisation Holder (MAH) pilot program, and as a result investments from venture capitalists increased in the nation’s biotech and pharmaceutical sector.        

Competitive Scenario:

The key players operating in the global drug discovery outsourcing market are –

Charles River Laboratories, Albany Molecular Research, Pharmaceutical Product Development LLC., Jubilant Biosys, Thermo Fisher Scientific Inc., Dalton Pharma Services, Laboratory Corporation of America Holdings, WuXi AppTec, Domainnex, Viva Biotech Ltd.

Connect to Analyst @ https://www.decisionforesight.com/speak-analyst/DFS020188 

How will this Market Intelligence Report Benefit You?

The report offers statistical data in terms of value (US$) as well as Volume (units) till 2030.

Exclusive insight into the key trends affecting the Global Drug Discovery Outsourcing industry, although key threats, opportunities and disruptive technologies that could shape the Global Drug Discovery Outsourcing Market supply and demand.

The report tracks the leading market players that will shape and impact the Global Drug Discovery Outsourcing Market most.

The data analysis present in the Global Drug Discovery Outsourcing Market report is based on the combination of both primary and secondary resources.

The report helps you to understand the real effects of key market drivers or retainers on Global Drug Discovery Outsourcing Market business.

The 2021 Annual Global Drug Discovery Outsourcing Market offers:

100+ charts exploring and analysing the Global Drug Discovery Outsourcing Market from critical angles including retail forecasts, consumer demand, production and more

15+ profiles of top producing states, with highlights of market conditions and retail trends

Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

Benchmark wholesale prices, market position, plus prices for raw materials involved in Global Drug Discovery Outsourcing Market type

Buy This Premium Research Report@ https://www.decisionforesight.com/checkout/DFS020188 

About Us:

Decision Foresight is a market research organization known for its reliable and genuine content, market estimation and the best analysis which is designed to deliver state-of-the-art quality syndicate reports to our customers. Apart from syndicate reports, you will find the best market insights, strategies that will help in taking better business decisions on subjects that may require you to develop and grow your business-like health, science, technology and many more. At Decision Foresight, we truly believe in disseminating the right piece of knowledge to a large section of the audience and cover the in-depth insights of market leaders across various verticals and horizontals.

Contact:

Email: sales@decisionforesight.com

For Latest Update Follow Us:

https://www.facebook.com/Decision-Foresight-110793387201935

https://twitter.com/DecisionFs

https://www.linkedin.com/company/decision-foresight/

[marketresearchhealthcarefuture]

Active Pharmaceutical Ingredients Market Top Companies Growth, Statistics Data, Upcoming Trends 2027

Market Overview

Active Pharmaceutical Ingredient Market size is anticipated to disclose a 4.96% CAGR and touch USD 215,125.4 Million by 2023. The active pharmaceutical ingredients share price has risen incrementally over the past few years due to medicinal properties. The drugs taken together with combined therapy have numerous active ingredients to treat a range of disorders. The various types of active pharmaceutical ingredients are prime elements in the production of drugs, and this global market is estimated to experience optimistic growth in the upcoming period.

also read @ https://www.medgadget.com/2019/12/share-valuation-of-active-pharmaceutical-ingredients-api-market-to-touch-usd-215125-4-million-during-2019-to-2023-marketresearchfuturr.html

Active Pharmaceutical Ingredients Market Segmentation

The worldwide API market has been segmented on the basis of manufacturing process, type of synthesis, API formulation, application, molecule.

In terms of manufacturing, the market can be fragmented into captive manufacturing and contract manufacturing. Out of these, the contract manufacturing segment can expect a profitable run during the review period at the highest growth rate, backed by the increasing trend of outsourcing of API manufacturing by the pharmaceutical companies, which lets them focus more on core competencies.

Depending on the synthesis, the market is considered for synthetic and biotech, wherein the synthetic API market is set to be unbeatable with the maximum share of the global market. Meanwhile, the biotech segment has displayed a considerable growth pattern in recent years, which is expected to surge further at a relatively higher CAGR owing to the reduced side effects of biotech synthesis. Furthermore, the biotech segment is split into monoclonal antibodies, recombinant proteins, vaccines, and others. At present, the monoclonal antibodies segment holds the top position, whereas the recombinant proteins segment is slated to expand at the fastest rate during the appraisal period as recombinant proteins find an increasing number of applications within the pharmaceutical industry.

With respect to the API formulation, the market is categorized as generic API and innovative API. Growing patent expirations have been responsible for the leading position of the generic API segment, at a projected CAGR of 4.62% during the conjectured time frame.

The market, application-wise, can be broken down into cardiovascular disease, oncology, neurological disorders, orthopedic disorders, respiratory, gastrointestinal, urology, and others. Here, the oncology segment is the current holder of the biggest market share, since the occurrences of cancer has surged at a substantial pace around the world. The segment is deemed to rise at a growth rate of 5.48% in the coming years.

The API market, on the basis of molecule, caters to small molecule and large molecule. Although the report identified the small molecule segment as the largest market in 2017, the large molecule segment is reckoned to cross the former’s valuation at a higher CAGR in the near future. The main reasons being the increasing focus on research and development of advanced APIs, including biologics that strive to meet with the unmet needs of patients.

Active Pharmaceutical Ingredients Market Regional Outlook

active pharmaceutical ingredients market include South America, Europe, Asia Pacific, North America, and the Middle East & Africa.

North America is spearheading the API market growth in the Americas, which in turn is leading the global market with the largest share. The crucial factors backing the said growth include the presence of a large number of prominent companies within the region. In addition, countries like the United States (U.S.) and Canada note high occurrences of chronic as well as neurological diseases, which is believed to be a prominent driver of the regional market growth.

Europe has bagged the second spot in the global API market, backed by the increasing number of initiatives within the region that support the development of generic drugs. Moreover, improving pricing, as well as reimbursement policies coupled with a huge number of manufacturing activities, is presenting multiple growth opportunities to the regional market.

As the active pharmaceutical ingredients market has reached the maturity phase in the developed countries around the globe, the market focus is shifting towards the Asia Pacific. This factor has substantiated the region as the fastest-growing market globally. The presence of a humungous patient population within countries like India and China paired with the rising incidences of chronic diseases in the region is poised to benefit the market in the subsequent years. On top of that, availability of cheap labor and need for low investments in infrastructure are encouraging several renowned pharmaceutical vendors to outsource manufacturing to Asia Pacific, opening the door for further market success.

Industry News

April 2019

OlonS.p.A., a global Active Pharmaceutical Ingredients (API) contract development and manufacturing organization (CDMO), has acquired a manufacturing facility in India. The facility’s primary product will be Rifampicin, which is used for treating a variety

Browse complete summary of this research report @ https://www.marketresearchfuture.com/reports/active-pharmaceutical-ingredients-market-1385

RELATED REPORTS

Global Digestible Sensors Market Research Report - Forecast to 2027

Global Blood Glucose Test Strip Market Research Report - Forecast to 2027

Global Urology Devices Market Research Report - Forecast to 2027

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

[blueweave]

Global Leukapheresis Market Gaining Momentum—Projected to Reach Worth USD 87.5 Billion in 2027

A study recently conducted by the strategic consulting and market research firm, BlueWeave Consulting revealed that the global leukapheresis market was worth USD 51.6 billion in 2020, and is further projected to reach USD 87.5 billion by 2027, at a CAGR of 7.8% during 2021-2027 (forecast period). The growing number of blood donors worldwide, combined with the growing number of cell-based therapies for the treatment of leukemia, are driving the demand for the global leukapheresis market. Additionally, rising investments by major players in research activities, along with the rising approvals for the process of isolating white blood corpuscles (WBC) for R&D activities are also driving the market growth during the forecast period.

Increasing Number of Blood Cancer Patients Driving Market Growth

Leukemia is a type of blood cancer that develops in the blood and bone marrow. It occurs when the body produces an abnormally large number of white blood cells, interfering with the bone marrow's ability to produce red blood cells and platelets. India is considered a rapidly growing economy that ranks second only to China in terms of population. However, an increase in cancer cases over the last decade has become a major public health issue in this steadily developing nation. Cancer affects a significant number of people in the United States as well. One individual in the United States (US) is diagnosed with blood cancer every three minutes, according to the Leukemia & Lymphoma Society. Leukemia, lymphoma, and myeloma are expected to account for 9.9 % of the estimated 1,806,590 new cancer cases diagnosed in the United States in 2020. It accounts for 34% of all blood cancer cases. The growing number of leukemia patients who need leukapheresis for treatment drives the market growth.

Download Free Sample Report: https://www.blueweaveconsulting.com/global-leukapheresis-market-report/report-sample

Increasing Number of Blood Donations

An increasing number of blood donors globally has positively impacted the market growth for the global leukapheresis market. Blood transfusions using donated cells from healthy volunteers helps replace red cells, platelets, and other blood components. Patients with leukemia often take chemotherapy medications, which may temporarily impair blood cells and depress the immune system. Blood cancer patients need healthy red blood cells, which can be achieved by blood donation. According to the WHO, 40 % of the 118.5 million blood donations received worldwide are collected in high-income countries, which account for 16 % of the world's population. Furthermore, the increasing number of blood donation camps organized by hospitals, NGOs, research societies, and universities encourages people to donate blood. As a result, the number of blood donors is growing, pushing the market growth even further.

Acute Lymphocytic Leukemia (ALL) Caters the largest share in the Market by Indication

Based on indication, ALL caters to the largest share in the global leukapheresis market. ALL is the most common childhood cancer. It occurs when the DNA of a bone marrow cell becomes faulty. Swollen lymph nodes, bruising, fever, bone pain, gum bleeding, and repeated infections are all possible symptoms. Acute lymphocytic leukemia is the most common form of cancer that affects children and adults. People who have undergone some forms of chemotherapy and radiation therapy for other types of cancer may be at a higher risk of developing acute lymphocytic leukemia. The American Cancer Society predicts that there will be approximately 5,690 new cases of Acute Lymphocytic Leukemia in the United States in 2021 (including both children and adults) and approximately 1,580 deaths from the same.

Impact of COVID-19

Following WHO's declaration of COVID-19 as a pandemic, governments around the world proposed stringent public health initiatives to limit the virus's spread. Cancer research centers, cancer care clinics, and cancer charities have all suffered greatly as a result of stringent policies and a shortage of supplies. As a result of COVID-19, the global leukapheresis market experienced a downfall. Furthermore, restricted access to clinics, combined with social distancing norms, and total lockdown declared by several countries, resulted in a slowdown in patient flow and referral, affecting market development. Cancer screenings dropped dramatically during the COVID-19 outbreak. Repeated cervical cancer screening dropped by 68 % in the first 15 weeks of 2020 in the United States, while breast cancer screening dropped by 17%, with more dramatic drops in areas where the epidemic was strongest.

Global Leukapheresis Market: Regional Insights

Geographically, the global leukapheresis market is categorized into North America, Europe, the Asia-Pacific, the Middle East & Africa, and Latin America. The Asia-Pacific region is expected to be the fastest-growing region during the forecast period, owing to an increase in the number of patients, especially in India and China. The growing number of geriatric patients in the area, especially in India, China, and Japan, is driving the expansion. Furthermore, increased healthcare awareness and the increasing demand for early diagnosis of patients in Asia-Pacific, as well as growth in outsourcing activities, drive market growth.

Competitive Landscape

The high growth potential of the leukapheresis market has attracted a host of new entrants, providing a lucrative opportunity. The arrival of new entrants has resulted in more competitive conditions among long-established service providers. Companies like Haemonetics Corporation and Charles River Laboratories are investing in and securing lucrative contracts that will enable humanity to have access to cutting-edge technology in the future.

Some of the key players include Terumo BCT Inc., Lonza Group AG, Puri Blood Medical Co. Ltd, Beijing ZKSK Technology Co. Ltd, Guangzhou Daji Medical Science and Technology Co. Ltd, Miltenyi Biotec, Charles River Laboratories, Caltag Medsystems Limited, Macopharma, Haemonetics Corporation, Asahi Kasei Medical Co. Ltd, Stem Express, LLC, and other prominent players. Companies are rapidly engaging in acquisitions, partnerships, and mergers to boost their production capacity, product range, and competitive differentiation.

In February 2021, Cognate BioServices, a premier cell and gene therapy contract production and manufacturing organization (CDMO), and Cobra Biologics, its gene therapy subsidiary, were acquired by Charles River Laboratories. As a result of the proposed acquisition, Charles River will become a leading science partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution.

Don’t miss the business opportunity of the global leukapheresis market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the global leukapheresis market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the ­­­leukapheresis market, along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

[newmarketplace]

On What Grounds Would The Active Pharmaceutical Ingredient Market Grow Between Forecast Years?

Prevalence of chronic diseases is constantly on the rise across the world. This is leading to a major health burden on governments and the society in general. Out of these, cardiovascular diseases make up around half of the total deaths caused by chronic diseases. According to the World Health Organization, in 2016, ischemic heart disease and stroke accounted for around 27% of total deaths, worldwide. Chronic obstructive pulmonary disease was the third most cause of death in the same years. These non-communicable diseases were major causes of deaths globally, ranging from 37% in lower economies and 88% in countries with high income.

Rising cases of chronic diseases is surging the need for pharmaceutical products, thereby increasing the need for pharmaceutical ingredients (APIs), especially small molecules.

Persistence Market Research predicts that the global active pharmaceutical ingredients market to exhibit a CAGR above 4% over the forecast period (2021-2031).

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/11260

Companies covered in Active Pharmaceutical Ingredient Marke Report

Pfizer Inc.

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

Cipla Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

GlaxoSmithKline plc

Hepalink Group

Lonza

Merck & Co. Inc.

Sandoz International GmbH

Aurobindo Pharma Limited

Fresenius Kabi LLC

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/11260

Key Takeaways from Market Study  

Non-controlled substances hold over half of the small molecule API market share, making them the predominant growth contributing factor.

Pharmaceutical and biopharmaceutical companies, combined, to contribute over 70% of the market revenue.

Major markets for active pharmaceutical ingredients to be East Asia, South Asia, North America, and Europe.

China and India to be the most lucrative markets for APIs.

Due to the impact of COVID-19, the API market saw a slight decline in growth in 2020, at 3.4%.

“Rising prevalence of chronic disorders and increasing research on small molecule APIs are expected to propel growth of the global active pharmaceutical ingredients market over the coming years,” says a Persistence Market Research analyst.

Access Full Report @https://www.persistencemarketresearch.com/checkout/11260

Advancements in API Manufacturing

API manufacturing will require implementation of continuous new technologies and tools to speed up the process and deliver consistent quality products. Hence, major players are highly focused on the production of optimized APIs with technological advancements in processes such as powder handling, lyophilization, process control, continuous flow chemistry, and process control.

Rise in Outsourcing to Merchant Companies

Even if big pharma players have established facilities for the production of APIs and pharma products, the trend of outsourcing is still on the rise. Many companies are outsourcing their requirements to cut costs on expensive equipment, manpower, and infrastructure. It is estimated that 40% of pharma products are manufactured by third-party vendors.

For instance, AstraZeneca used to have several manufacturing centers in North America, but currently, only 15% of its APIs are made in-house, and the company is looking to outsource all manufacturing overseas. From the last 20 years or so, directly sourcing APIs from China and India has increased due to the production capabilities of these countries. Also, stringent regulations in the West have attracted companies toward China and India.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the active pharmaceutical ingredients (API) market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031, on the basis of API (small molecules [controlled substances {natural opioids and semi-synthetic/synthetic opioids}, non-controlled substances {NSAIDs, anti-infective, antimicrobial, oral anti-diabetics, anti-hypertensive, and others}, and HPAPI], peptides & oligonucleotides, carbohydrate drugs, and steroidal drugs), end user (contract manufacturing organizations (CMOs), pharmaceuticals, contract development & manufacturing organizations (CDMOs), and compounding pharmacies), across seven key regions of the world.

About Us :-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Contact us:

Persistence Market Research Address – 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – sales@persistencemarketresearch.com Website – https://www.persistencemarketresearch.com

[linhgd9]

Global Biopharmaceutical CMO Market Assessment 2021-2026 – Impact of COVID-19, Case Study Analysis, Key Opportunities , Major Players and Growth Analysis

The global ”biopharmaceutical contract manufacturing organizations“ market is projected to showcase an impressive growth owing to the increasing need to outsource the manufacturing process in the biopharmaceutical industry, observes Fortune Business Insights

in an upcoming report, titled, “Biopharmaceutical CMO Market Size, Share & Industry Analysis, By Service Type (Bio-manufacturing [Upstream, Downstream] Fill & Finish Operations, Analytical & QC Studies, Packaging), By Product ( Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, Others) and Regional Forecast, 2020-2027.” These organizations allow pharmaceutical companies to outsource some aspects of their business, which saves their valuable time and aids them to focus on the development of drugs.

The COVID-19 contagion has compelled the world to develop a vaccine for the virus at a rapid pace. This is expected to drive the market for biopharmaceutical CMOs. However, the scale at which the production is assumed to take place is a major challenge for most of the renowned players. At Fortune Business Insights

, we are providing actionable insights by closely studying multiple aspects of the current scenario. We are also offering firsthand information on various market trends through our comprehensive research reports.

Request a Sample Copy of the Research Report: 

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/biopharmaceutical-cmo-market-103346

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

To get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/biopharmaceutical-cmo-market-103346

Increasing Adoption of CMOs in Biopharmaceutical Space to Drive Growth

The rising demand for specialized work force and the high cost associated with the facility setup have resulted in the increasing adoption of CMOs in the biopharmaceutical industry. This is expected to drive the growth of the global biopharmaceutical CMO market. In addition, increasing mergers and acquisitions among key players and rising venture capital investments are some of the major factors enhancing the demand, which is anticipated to further strengthen growth. However, the rising competition among prominent players is expected to restrain growth.

Regional Analysis:

The global biopharmaceutical CMO market is expected to be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the global biopharmaceutical CMO market due to the rising demand for CMOs because of the presence of several small and mid-sized players with limited sources in this region. Europe is likely to have substantial market growth throughout the forecast period owing to the robustness of venture capital investments, and the increasing availability of venture funds. Asia Pacific is expected to witness growth with the highest CAGR during the forecast period due to the increasing mergers and acquisitions among key players and growing demand for CMOs. On the other hand, Latin America and the Middle East and Africa is projected to have a lucrative growth in the biopharmaceutical CMO market in the upcoming years.

Presence of Major Biopharmaceutical Facilities in U.S. to Help North America Dominate

The U.S. being home to the largest market for biopharmaceuticals, North America is projected to lead the global biopharmaceutical CMO market. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), the firms present in the U.S. collectively conduct more than 50% of the world’s R&D in pharmaceuticals.

The market in Asia Pacific is estimated to expand at rapid pace during the forecast period. Cost associated benefits, such as, lower labor costs and operating costs from outsourcing in Asian countries are expected to drive the growth in the region.

Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/biopharmaceutical-cmo-market-103346

A List of Key Manufacturers Operating In the Global Biopharmaceutical CMO Market Report:

Rentschler Biotechnologie SE

Lonza

Boehringer Ingelheim GmbH

Kemwell Biopharma

Inno Bio Ventures Sdn Bhd

ProBioGen AG

FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

TOYOBO CO., LTD.

Others

Adopting Expansion Strategies to Aid Key Players to Gain Share

Prominent enterprises operating in the global biopharmaceutical CMO market are focusing on expanding their businesses. They are adopting expansion strategies, mergers and acquisitions, in order to increase their shares. For instance, in April 2016, Recipharm announced the acquisition of the Pharmaceutical Contract Development and Manufacturing Operations (CDMO) of Kemwell.

In November 2019, JW Pharmaceutical launched its joint-stock company and a CMO business in Vietnam.

In February 2017, Sanofi and Lonza entered into a strategic partnership to establish a large-scale biologics production facility in Switzerland.

Get your Customized Research Report:

https://www.fortunebusinessinsights.com/enquiry/customization/biopharmaceutical-cmo-market-103346

What are the key segments in the market?

By Service Type

Bio-manufacturing

o Upstream

o Downstream

Fill & Finish Operations

Analytical & QC Studies

Packaging

By Product

Monoclonal Antibodies

Vaccines

Recombinant Proteins

Antisense, RNAi, & Molecular Therapy

Others

By Geography

North America (USA, Canada)

Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

Latin America (Brazil, Mexico, Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

With tables and figures helping analyse worldwide Global biopharmaceutical CMO Market Forecast provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

About Us:

Fortune Business Insights

offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights

we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights

Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Fortune Business Insights

LinkedIn | Twitter | Blogs

  Related Reports:

Europe Urinary Drainage Bags Market

Europe Urinary Drainage Bags Market

Europe Urinary Drainage Bags Market

Europe Urinary Drainage Bags Market

Europe Urinary Drainage Bags Market

Laser Hair Removal Market 

Laser Hair Removal Market 

Laser Hair Removal Market 

Laser Hair Removal Market 

Laser Hair Removal Market 

from NeighborWebSJ https://ift.tt/3whhUT4 via IFTTT

from WordPress https://ift.tt/39viF1k via IFTTT